Wellness market report touts $275bn by 2035; Europe’s policy lever is trust

# Wellness market report touts $275bn by 2035; Europe’s policy lever is trust

A 146-page industry study released on July 10, 2026 says the global “advanced therapeutics (aging and wellness)” market is projected to expand from $154.89 billion in 2024 to $275.35 billion by 2035, implying a 5.51% compound annual growth rate. The report frames the category around nutritional formulations and functional bioactives, and names Abbott, Nestlé, Herbalife and Amway among the companies it profiles.

For the euro area, the headline numbers matter less than the mechanism: if preventive health products keep moving from the margins to the mainstream, the economic question becomes who polices claims, who pays, and how quickly consumer demand translates into measurable health outcomes.

In the euro area, health spending and consumer regulation sit mostly with national governments and EU-wide rulemaking rather than the European Central Bank. The ECB’s role is indirect: it sets monetary conditions for the 20 countries that use the euro, and it watches inflation dynamics that can be affected by services costs, demographics, and public spending choices.

Some of the key euro-area acronyms that often get pulled into any “macro” discussion do not directly apply to this wellness-report story. The ECB’s Transmission Protection Instrument (TPI) is a bond-buying backstop designed to counter unwarranted market fragmentation; Outright Monetary Transactions (OMT) is an earlier conditional sovereign-bond purchase tool; and HICP is the Harmonised Index of Consumer Prices, the euro area’s headline inflation gauge. None of those tools regulates supplements or wellness claims, but they shape the financing environment in which households and governments decide what they can afford.

What it means for the euro area

If the report’s growth trajectory proves directionally right, euro-area implications show up through micro channels that add up: household budgets, pricing power for consumer-health brands, and the regulatory perimeter around health claims. The study itself flags “regulatory challenges,” which is where Europe is structurally different from the US-led framing in the release: consumer trust tends to be built through tighter definitions of what can be marketed as therapeutic versus supportive, and through enforcement that limits exaggerated claims.

On markets, the transmission is second-order. A sustained shift toward preventive health can lift demand for specialised food, nutrition, and consumer-health products, supporting revenue expectations for companies with European exposure; but it can also raise political scrutiny if products are priced as quasi-medical while evidence remains contested. That tension can feed into sectoral investment cycles and, over time, into public spending debates if governments consider reimbursements or formal integration into care pathways.

A falsifiable test will come from policy and enforcement rather than forecasts: by 2026-12-31, watch for EU or national regulators to take a clear, public action on wellness-product marketing claims that aligns with the report’s warning about regulatory friction. If rules tighten or enforcement rises (condition right), market growth in Europe is more likely to concentrate in products with stronger substantiation and established distribution. If enforcement remains light or fragmented (condition wrong), the category may grow faster in volume but carry higher reputational and litigation risk for brands operating across borders.